Lipicard's Platrol(R) - the Safest Anti-Platelet Drug - the Fastest to Market as Well!HYDERABAD, India -- Platrol[R] has demonstrated 40% more efficacy and negligible toxicity in limited clinical trials resulting in higher therapeutic index compared to Aspirin, Clopidogrel and other anti-platelet drugs. And Platrol[R]'s inherent sustained release property makes it even better as a long-term cardio-protective drug. The most talked about antiplatelet drug currently in research pipeline is Prasugrel - ADP (1) (Automatic Data Processing) Synonymous with data processing (DP), electronic data processing (EDP) and information processing. (2) (Automatic Data Processing, Inc., Roseland, NJ, www.adp. receptor antagonist similar to Clopidogrel. Prasugrel is being jointly developed by Daiichi Sankyo and Eli Lily. According to Eli Lily, Prasugrel in Phase I trials using healthy volunteers has shown better inhibition of platelet aggregation than Clopidogrel, but the safety profile is comparable to that of Clopidogrel. Prasugrel essentially has higher efficacy but no better toxicity profile as compared to Clopidogrel. However, Prasugrel has to go through an intensive Phase III clinical program to translate the better platelet inhibition seen in Phase I studies to improved clinical outcomes in terms of reducing MI and other CAD instances and death compared to Clopidogrel - essentially an expensive and time consuming study similar to CAPRIE CAPRIE Cardiology A clinical trial–Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events which compared the efficacy of the antiplatelet agent, clopidogrel, with aspirin therapy as a stroke prophylaxis. See Clopidogrel. study done for establishing Clopidogrel's marginal superiority over Aspirin. Platrol[R] has multiple advantages as a novel high therapeutic index antiplatelet drug and definitely scores over Prasugrel: a. Much better safety profile - negligible GI toxicity as compared to Clopidogrel and by inference Prasugrel. b. Faster route to market as it can get approved for other indications as well. c. While Clopidogrel might become extinct on arrival of Prasugrel (both targeting P2Y12 receptors), Platrol[R] will be used for long term preventive cardio-protection as well as in tandem with Prasugrel as Platrol inhibits Thromboxane thromboxane /throm·box·ane/ (-bok´san) either of two compounds, one designated A2 and the other B2. Thromboxane A2 is synthesized by platelets and is an inducer of platelet aggregation and platelet release functions and is a A 2 synthesis. Prasad Prasāda (Sanskrit: प्रसाद), prasād/prashad (Hindi), Prasāda in (Kannada), prasādam (Tamil), or prasadam Sambaru, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Lipicard Technologies feels that Platrol is a truly safe antiplatelet drug for long term cardio-protection as well as for reducing the adverse clinical incidences after interventional cardiac surgery. About Lipicard Technologies: Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardio protection in collaboration with Life Enhancing Technologies LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . USA. PLATROL[R] is the first safe antiplatelet drug being developed for cardio-protection. Next in line are the integrated Lipid management drug for increasing HDL (Hardware Description Language) A language used to describe the functions of an electronic circuit for documentation, simulation or logic synthesis (or all three). Although many proprietary HDLs have been developed, Verilog and VHDL are the major standards. and lowering LDL LDL - ["LDL: A Logic-Based Data-Language", S. Tsur et al, Proc VLDB 1986, Kyoto Japan, Aug 1986, pp.33-41]. , and safe NSAIDs. PLATROL[R] is registered trademarks of Life Enhancing Technologies. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion